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Summary In the present study we have confirmed that approximately one third of human colorectal
carcinomas fail to express the HLA - A, B,C monomorphic determinant reactive with the W6/32 MAb, and
44% express class II HLA antigens as shown by reactivity with NFK-1 MAb. Reduced staining with the
W6/32 MAb was not always associated with loss of ,B2m. In addition, the expression of HLA-A2 and Bw4
class I specific haplotypes on normal colon epithelium and tumour biopsy tissue was assessed. All normal
colonic epithelia stained positively with MAb against A2 and Bw4 antigens, but a loss of these determinants
was shown on tumour biopsies from patients tissue typed for the respective specificities. Loss of the A2
haplotype was shown in 4 of 15 tumour tissue samples, and loss of Bw4 specificities in 5 out of 7 tissue
samples. The failure to detect specific loci determinants was not necessarily associated with loss of reactivity
with W6/32 MAb.
Class I and class II MHC antigens are essential for the
regulation of several immune functions. MHC class I
antigens operate as restriction elements in T-cell mediated
cytotoxicity, whilst class II antigens are involved in the
presentation of antigen to cells of the immune system
(Zinkernagel & Doherty, 1979; Benacerraf, 1981). Studies on
the expression of HLA antigens on tumour cells using
conventional tissue typing techniques have indicated that
altered expression of HLA antigens can occur (Pollack et al.,
1980; 1981). More recently, monoclonal antibodies against
HLA-A, B or C framework structures and the associated
beta-2 microglobulin (fl2m) have shown that a reduced
expression, and in some cases a complete loss of class I
antigens, is found in certain tumours (Fleming et al., 1981;
Daar & Fabre, 1983; Csiba et al., 1984; Momberg et al.,
1986). Inappropriate expression of HLA class II antigens has
been demonstrated in malignant melanoma, breast
carcinoma and colorectal cancer (Natali et al., 1983; Brocker
et al., 1984; Wilson et al., 1984; Daar & Fabre, 1983;
Rognum et al., 1983).
In a recent study Van den Ingh et al. (1987) failed to
demonstrate a correlation between the histological
characteristics of colorectal tumours and either the abnormal
expression of class II antigens or the loss of class I antigens;
adenomas and non-mucinous carcinomas were shown to
strongly express class I framework antigens. It is perhaps
significant that mucinous tumours, which have a poor
prognosis, showed loss of expression of HLA-antigens and
low numbers of infiltrating lymphocytes.
An additional study by Momberg et al. (1986) has
suggested that the loss of class I antigens from the surface of
colorectal tumour cells is related to a lower degree of
differentiation. These tumours, like the mucinous tumours,
have a poor prognosis which may indicate that loss of class I
determinants is associated with a more malignant phenotype.
Although definitive evidence for this has not yet been
documented, experiments in murine models of tumour
growth and metastasis suggest that loss of class I expression
may influence tumour progression. Transfection of class I
genes into tumours lacking expression was found to hinder
tumour growth and in some cases abrogate metastasis (Hui
et al., 1985; Wallich et al., 1985). In the present study, we
extend previous investigations by showing the loss of
individual A and B locus HLA-A2 and Bw4 antigen specifi-
cities on colon carcinoma cells, which was not necessarily
associated with a simultaneous loss of HLA monomorphic
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antigenic determinants. The HLA-A2 and Bw4 specific
monoclonal antibodies were chosen because of the relatively
high frequency of these antigens in the population, and their
availability. The results presented do not indicate that these
specificities are more prone to loss of expression than other
HLA class I polymorphic determinants.
Materials and methods
Patients and specimen collection
Patients admitted to the study were undergoing laparotomy
and resection of colorectal adenocarcinoma. Colorectal
tumours were classified by Dukes' staging, as type A, B or
C, depending on the degree of tumour invasion. Samples of
tumour tissue and normal colon, taken from a site 15cm
distant from the tumour, were collected from each patient,
wrapped in aluminium foil, sprayed with 'Supra-freezit'
(Sorrisol, Merseyside) and snap-frozen. All tissue samples
were stored at -80°C until frozen sections were cut using a
cryostat at a thickness of 5-1O0tm. A total of 30 patients
were included in the study and the majority of these were
tissue typed for HLA-A, B and C, using peripheral blood
lymphocytes from the patient and conventional lympho-
cytotoxicity techniques (typing antisera and complement).
Immunoperoxidase staining offrozen sections
Slides stored at -80°C were warmed to room temperature
and rehydrated in Tris-buffered saline (TBS). Following the
removal of excess TBS, 40,ul mouse monoclonal antibody
(MAb) (at the appropriate dilution in TBS) was laid onto
each section which was incubated for 40min in a humidified
atmosphere at room temperature. The sections were then
washed twice in TBS prior to the addition of 50,ul rabbit
anti-mouse peroxidase (Dako Ltd., Bucks.). The slides were
covered and left for 40min at room temperature and sub-
sequently washed twice in TBS, flooded with
diaminobenzidine (DAB) and with 0.5% (v/v) hydrogen
peroxide for 10min. Following washing of the slides in tap
water they were stained in Harris's haematoxylin and
mounted for examination under a light microscope.
Monoclonal antibodies
The following monoclonal antibodies (MAbs) were used in
the study: W6/32 directed against the monomorphic alpha
chain determinant of HLA-A, B, and C framework antigens
(Barnstable et al., 1978), was a gift from Dr W.F. Bodmer,
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London; anti-,B2m was purchased from Sera-tech Limited:
NFK-1 monoclonal antibody (Daar et al., 1984), which
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recognises a monomorphic determinant of human class II
antigens, including the products of the DR, DP and DQ loci,
was a gift from Dr S. Fuggle, Nuffied Department of
Surgery, John Radcliffe Hospital, Oxford: BB7.2 is an anti-
HLA-A2 monoclonal antibody (Brodsky et al., 1979) and
was kindly donated by Dr Bodmer, Imperial Cancer
Research Fund, London: 116.5.28 monoclonal antibody
recognises the HLA-Bw4 specificity and this reagent was
produced at Sheffield Blood Transfusion Centre by one of us
(KG) (unpublished). Anti-cytokeratin monoclonal antibody
was obtained from Amersham International plc, Bucks UK.
Tissue typing
HLA typing at A and B loci was performed using a standard
microlymphocytotoxicity assay with reagents specific for the
following antigens: A1, 2, 3, 9, 25, 26: 11, 28, 29, w30, w31:
B5, 7, 8, 44, 45, 13, 14, 15, 16, 17, 18, 21, 22, 27, 35, 37
WHO.
Results
Expression of monomorphic and polymorphic HLA
determinants on colon carcinoma cells
Using the MAb W6/32, uniform staining of epithelial and
interstitial cells in all normal colon mucosa was observed.
Similar staining was seen with the anti-fl2m MAb. In
contrast, a proportion of the colon tumour specimens
demonstrated variable staining patterns. In total, 7 out of 30
(23%) of the specimens examined showed loss of reactivity
with MAb W6/32; one specimen showing a complete loss of
reactivity with tumour cells, although in all cases the cells
within the stroma remained strongly positive (data not
shown). The remaining 23 tumour sections were uniformly
positive with MAb W6/32. Only 2 of the 7 tumour samples
which demonstrated heterogeneity of expression of the class
I a-chain also showed (in serial sections) a partial loss of
reactivity with anti-,B2m antibody. Using the MAb NFK-1,
which reacts with a monomorphic determinant of the class II
DP, DQ and DR antigens, none of the epithelial cells in
normal colon samples obtained from the 30 patients entered
into the study showed reactivity, although cells within the
interstitium (probably macrophages and B-cells) were
strongly stained. Forty-four per cent of the tumours
examined demonstrated foci of positively stained cells with
NFK-1 MAb 14, and these results are consistent with those
previously published. The epithelial nature of the cells in
both normal and tumour sections was confirmed by staining
serial sections with anti-cytokeratin MAb (data not shown).
Twelve of the 30 patients were shown to be positive for
HLA-A2 by conventional tissue typing techniques, and a
further three, who were not tissue typed, were included
because their normal colon epithelium stained positively with
MAb BB7.2 (specific for HLA-A2). With all patients,
normal colon epithelium showed intense staining with MAb
W6/32 and MAb BB7.2 (Table I). Assessment of tumour
sections from the patients revealed that 3 of the 15
specimens showed areas of positive and negative staining
with BB7.2 antibody, and in one further sample all epithelial
cells failed to react with this MAb. Two of the 4 tumour
samples showing reduced expression of the HLA-A2
specificity also had areas of tumour cells which were
negative with MAb W6/32, but the remaining two tumours
showed an absence of the A locus specificity without
detectable loss of the HLA class I framework antigen
(W6/32 reactive, BB7.2 non-reactive).
Tissues from 7 patients, who were Bw4 positive by tissue
typing were stained with the MAb 116.5.28 to determine
Table I Expression of HLA-A2 (BB7.2) and Bw4 (116.5.28) specificities on colorectal
tumour and normal colon epithelium of patients positively typed for those respective
antigens
Immunoperoxidase staining with monoclonal antibodies: Tissue:
Degreea Normal colon epithelium Tumour
Dukes' Of
Patient stage differentiation W6/32 BB7.2 W6/32 BB7.2
EB B W + + +1- +/-
RL B W + + +1- +/-
LN B M + + + -
IB B W + + + +/-
GB B M + + + +
CB B M + + + +
FB C W + + + +
FH B W + + + +
RP C M + + + +
CR B M + + + +
SS B M + + + +
RR B M + + * + +
DT C W + + + +
EE C P + + + +
EJ C M + + + +
W6/32 116-5-28 W6/32 116-5-28
HD C W + + +/- +/-
VP B M + + - -
FB B W + + + +/-
SS B M + + + ±/-
AR C M + + + +/
HS A W + + + +
CB B M + + + +
+, Section uniformly stained with antibody.
-, Negative staining of epithelial cells; +/-, section demonstrating areas of positively
and negatively stained cells.
'Tumours classified as well (W), moderately (M) or poorly (P) differentiated
adenocarcinomas.376 R.C. REES et al.
Figure 1 Tumour tissue from a patient (LN) tissue typed as
HLA-A2 positive; Upper panel: Adenocarcinoma cells stained
uniformly with W6/32 MAb.; Lower panel: Loss of staining
reaction with MAb BB 7.2 (anti-HLA-A2 specific), but stromal
cells stain positively.
whether tumour tissue demonstrated an altered expression of
the B locus of class I. Normal colon epithelium was stained
positively with both W6/32 and 116.5.28 MAbs (Table I),
whereas the tumour samples from these patients showed a
variable staining pattern. Of the 7 tumours examined, 4
showed a partial loss of 116.5.28 reactivity and one a
complete absence of detectable antigen. Three samples that
showed negative staining with MAb 116.5.28, reacted in
consecutive sections with MAb W6/32, indicating that
although a monomorphic antigen sequence of HLA class I
was present, the Bw4 specificity had been lost. Figure 1 shows
an example of tumour stained uniformly with W6/32 MAb, but
loss of reactivity with the BB7.2 MAb (anti-HLA-A2
specific). Of the tumours showing a loss of HLA-A2 specifi-
city, 3 out of 4 were well differentiated whereas the majority
of tumours showing no loss of antigenic expression were
moderately differentiated (only 3 out of 11 were well dif-
ferentiated). Within the group of 5 tumours showing a loss
of HLA-Bw4 antigen specificity, 2 out of 5 were well
differentiated (Table I). Tumours showing a loss of
polymorphic HLA determinants were classified mostly as
Dukes' stage B (7 out of 9 tumours were Dukes' B),
although no definite correlation could be established between
loss of specificity and disease stage.
Discussion
Cytotoxicity by T lymphocytes towards neoplastic cells relies
on the co-expression of specific antigenic determinants and
class I histocompatibility antigens (Zinkernagel and Doherty,
1979). Class I and II MHC antigens also have a role in the
induction and modulation of immune reactivity, including
the presentation of foreign antigens to class II restricted
helper T lymphocytes and target cell recognition by class I
restricted cytotoxic T lymphocytes. It is therefore important
to determine the aberrant expression of MHC antigens in
disease states, and many studies have shown that significant
changes in both class I and class II HLA antigens occur in
malignant disease (Fleming et al., 1981; Bhan and
DesMarais, 1983; Whitwell et al., 1984; Rowe & Beverley,
1984; Daar & Fabre, 1983; Csiba et al., 1984; Umpleby et
al., 1985; Momberg et al., 1986; Daar et al., 1982).
Approximately one third of colorectal tumours show
reduced staining with W6/32 MAb, which reacts with HLA-
A, B, C framework determinants (Momberg et al., 1986),
and this finding shows a relationship with poorly differen-
tiated tumours. Our results, showing a loss of W6/32
reactivity are consistent with previous reports.
The present study has also confirmed that class II HLA
antigens are expressed in approximately one third of the
tumours, and these results are similar to those reported by
others (Daar et al., 1982; Daar & Fabre, 1983; Csiba et al.,
1984). Recently the distribution of the D-region sub-locus
products in colorectal cancer has been reported (Ghosh et
al., 1986), where DR appeared as the prominent specificity,
but the expression of DR, DP and DQ determinants failed
to correlate with disease stage or degree of differentiation.
In previous reports MAbs have been used which showed
specificity for non-polymorphic determinants of HLA class I
molecules, where any loss of individual specificities of the
HLA A or B locus would not have been detected. In the
present study we have used two MAbs with specificity for
the HLA-A2 and HLA-Bw4 determinants (Brodsky et al.,
1979; Gelsthorpe, unpublished). Patients were tissue typed
for A2 or Bw4 either by conventional tissue typing, or, as in
three cases, by staining of normal colon mucosa with an A2
specific MAb. This allowed us to establish a group of 15
patients of known A2 haplotype, and 7 of Bw4 specificity.
To our knowledge, the loss of individual specificities on
colorectal tumours has not been previously reported. The
results show that loss of these determinants can occur
without the simultaneous loss of HLA framework
determinants reactive with the W6/32 MAb, or with anti-
,B2m MAbs. Thus, of three tumour biopsies showing a
partial, and one a complete loss of A2 specificity, two
samples stained intensely with W6/32 MAb. In addition, 7
patients were tissue typed as Bw4 positive, and tumours
from 4 of these showed a partial loss of reactivity with MAb
116.5.28 and one a complete loss of reactivity; however, in 3
of the tumours the absence of the specific Bw4 determinant
was not associated with a loss of reactivity to MAb W6/32.
The loss of A or B locus determinants of HLA class I
antigens is of considerable interest, particularly in relation to
the possible interaction of these specificites with cytotoxic T
lymphocytes, where absence of defined HLA-A or -B
specificities could theoretically influence T-cell antigen
recognition and cytotoxic capability. It is not clear whether
the failure to express individual class I loci is a consequence
of alteration in antigenic structure and spacial arrangement,
a failure to transcribe genetic information coding for the
subdomain region of the HLA molecule, or possibily the
masking of epitopes expressed on finite specifities resulting in
the failure of the monoclonal antibody to recognise and bind
to that epitope. This latter explanation is less likely, since
loss of antigen expression was associated with distinct 'foci'
of epithelial cells which were completely unreactive with
MAbs. From this and recent studies, it is evident that
primary colorectal carcinoma cells are heterogeneous with
regard to framework and A and B locus antigen expression,
although it is not clear whether altered HLA antigen
expression is associated with other biological properties such
as tumour invasion and metastases. The finding that
polymorphic regions of HLA class I antigens may be lost in
tumours underlines the complex nature of HLA expression.
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